BCL2 and chronic myelogenous leukemia, BCR-ABL1 positive: The extreme clinical responses to ABT-199 seen in patients with CLL and AML as well as ongoing clinical trials of ABT-199 in patients with CML sets forth a legitimate role for select Bcl-2 antagonists in the treatment of “liquid” tumors.